Lorlatinib
A third-generation ALK/ROS1 inhibitor designed to overcome resistance to earlier ALK inhibitors in non-small cell lung cancer. It is engineered to penetrate the blood-brain barrier, making it effective against brain metastases.
Peso molecular
406,4000 g/mol
LogP
1,50
TPSA
110,00 Ų
Regla de cinco de Lipinski
Cumple
Áreas terapéuticas
Mecanismo de acción
Inhibits anaplastic lymphoma kinase (ALK), a receptor tyrosine kinase whose rearrangement or mutation drives oncogenic signaling in certain cancers.
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Inhibits anaplastic lymphoma kinase (ALK), a receptor tyrosine kinase whose rearrangement or mutation drives oncogenic signaling in certain cancers.
Estructura 2D
Cite this structure
Embed this structure
SMILES
C[C@H]1Oc2cc(cnc2N)-c2c(nn(C)c2C#N)CN(C)C(=O)c2ccc(F)cc21
InChI
InChI=1S/C21H19FN6O2/c1-11-15-7-13(22)4-5-14(15)21(29)27(2)10-16-19(17(8-23)28(3)26-16)12-6-18(30-11)20(24)25-9-12/h4-7,9,11H,10H2,1-3H3,(H2,24,25)/t11-/m1/s1
Molecular Formula
C21H19FN6O2
HBD / HBA
1 / 7
Enlaces Rotables
0
Átomos Pesados
30
No targets recorded
Target interaction data is not yet available for this drug.
No interactions recorded
Drug interaction data is not yet available for this compound.
No side effects recorded
Side effect data is not yet available for this drug.
Preguntas frecuentes
A third-generation ALK/ROS1 inhibitor designed to overcome resistance to earlier ALK inhibitors in non-small cell lung cancer. It is engineered to penetrate the blood-brain barrier, making it effective against brain metastases.
Inhibits anaplastic lymphoma kinase (ALK), a receptor tyrosine kinase whose rearrangement or mutation drives oncogenic signaling in certain cancers.
Yes, Lorlatinib is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL3286830. Open-access bioactivity database.
- PubChem — National Center for Biotechnology Information (NCBI). CID 71731823. Chemical information database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="lorlatinib"></div>Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/lorlatinib/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/lorlatinib/Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/lorlatinib/)Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="lorlatinib"></drugfyi-drug>